Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The presence of C/EBPα and its degradation are both required for TRIB2-mediated leukaemia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The focal adhesion-associated proteins DOCK5 and GIT2 comprise a rheostat in control of epithelial invasion

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A comprehensive profile of recurrent glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Prdm5 suppresses Apc(Min)-driven intestinal adenomas and regulates monoacylglycerol lipase expression

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The splicing factor RBM25 controls MYC activity in acute myeloid leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub regulating granulo-monocytic fates

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Differences in Cell Cycle Status Underlie Transcriptional Heterogeneity in the HSC Compartment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Human adult HSCs can be discriminated from lineage-committed HPCs by the expression of endomucin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • C O'Connor
  • F Lohan
  • J Campos
  • E Ohlsson
  • M Salomè
  • C Forde
  • R Artschwager
  • R M Liskamp
  • M R Cahill
  • P A Kiely
  • B Porse
  • K Keeshan
Vis graf over relationer

C/EBPα (p42 and p30 isoforms) is commonly dysregulated in cancer via the action of oncogenes, and specifically in acute myeloid leukaemia (AML) by mutation. Elevated TRIB2 leads to the degradation of C/EBPα p42, leaving p30 intact in AML. Whether this relationship is a cooperative event in AML transformation is not known and the molecular mechanism involved remains elusive. Using mouse genetics, our data reveal that in the complete absence of C/EBPα, TRIB2 was unable to induce AML. Only in the presence of C/EBPα p42 and p30, were TRIB2 and p30 able to cooperate to decrease the latency of disease. We demonstrate that the molecular mechanism involved in the degradation of C/EBPα p42 requires site-specific direct interaction between TRIB2 and C/EBPα p42 for the K48-specific ubiquitin-dependent proteasomal degradation of C/EBPα p42. This interaction and ubiquitination is dependent on a critical C terminal lysine residue on C/EBPα. We show effective targeting of this pathway pharmacologically using proteasome inhibitors in TRIB2-positive AML cells. Together, our data show that excess p30 cooperated with TRIB2 only in the presence of p42 to accelerate AML, and the direct interaction and degradation of C/EBPα p42 is required for TRIB2-mediated AML.Oncogene advance online publication, 21 March 2016; doi:10.1038/onc.2016.66.

OriginalsprogEngelsk
TidsskriftOncogene
Vol/bind35
Udgave nummer40
Sider (fra-til)5272-5281
ISSN0950-9232
DOI
StatusUdgivet - 21 mar. 2016

ID: 46359285